Concentrations of trovafloxacin in colonic tissue and peritoneal fluid after intravenous infusion of the prodrug alatrofloxacin in patients undergoing colorectal surgery

American Journal of Surgery

Volumn 176, Issue 6 A, 1998, Pages 14S-17S

  Melnik, George ^a   Schwesinger, Wayne H ^a   Dogolo, Lisa C ^b   Teng, Renli ^b,c   Vincent, John ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^c Astra Merck   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALATROFLOXACIN; PRODRUG; TROVAFLOXACIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; COLON MUCOSA; COLORECTAL SURGERY; DRUG DETERMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG PENETRATION; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MINIMUM INHIBITORY CONCENTRATION; PERITONEAL FLUID; PRIORITY JOURNAL; SAMPLING;

EID: 0032466996     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(98)00214-1     Document Type: Article

References (17)

1. Briggs Gooding B, Jones RN. In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrob Agents Chemother. 1993;37:349-353.
2. Eliopoulos GM, Klimm K, Eliopoulos CT, et al. In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram positive bacteria. Antimicrob Agents Chemother. 1993;37:366-370.
3. Spangler SK, Jacobs MR, Appelbaum PC. Activity of CP-99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes. Antimicrob Agents Chemother. 1994;38: 2471-2476.
4. Neu HC, Chin NX. In vitro activity of the new fluoroquinolone CP-99,219. Antimicrob Agents Chemother. 1994;38:2615-2622.
5. Coque TM, Singh KV, Murray BE. Comparative in-vitro activity of the new fluoroquinolone trovafloxacin (CP-99,219) against gram-positive cocci. Antimicrob Chemother. 1996;37:1011-1016.
6. Fuchs PC, Barry AL, Brown SD, Sewell DL. In vitro activity and selection of disk content for disk diffusion susceptibility tests with trovafloxacin. Eur J Clin Microbiol Infect Dis. 1996;15:678-682.
7. Wexler HM, Molitoris E, Molitoris D, Finegold SM. In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria. Antimicrob Agents Chemother. 1996;40:2232-2235.
8. Felmingham D, Robbins MJ, Ingley K, et al. In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates. Antimicrob Chemother. 1997;39(suppl B):43-49.
9. Girard AE, Girard D, Gootz TD, Faiella JA, Cimochowski CR. In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptiococcus pneumoniae, and Bacteroides fragilis. Antimicrob Agents Chemother. 1995;39:2210-2216.
10. Thadepalli H, Reddy U, Chuah SK, et al. In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone, in experimental intra-abdominal abscesses caused by Bacteroides fragilis and Escherichia coli. Antimicrob Agents Chemother. 1997;41:583-586.
11. Onderdonk AB. Efficacy of trovafloxacin (CP-99,219), a new fluoroquinolone, in an animal model of intra-abdominal sepsis. Infect Dis Clin Prac. 1996;5(3 suppl):S117-S119.
12. Teng R, Harris SC, Nix DE, et al. Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. Antimicrob Chemother. 1995;36:385-394.
13. Teng R, Liston TE, Harris SC. Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers. Antimicrob Chemother. 1996;37:955-963.
14. Vincent J, Venitz J, Teng R, et al. Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin. Antimicrob Chemother. 1997;39(suppl B):75-80.
15. Nichols RL. Surgical infections: prevention and treatment -1965 to 1995. Am J Surg. 1996;172:68-74.
16. Antimicrobial prophylaxis in surgery. Med Lett Drugs Ther. 1995;37:79-82.
17. Brighty KE, Gootz TD. The chemistry and biological profile of trovafloxacin. J Antimicrob Chemother. 1997;39(suppl B):1-14.